京新药业(002020) - 2023 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2023 was ¥988,985,036.16, representing a 6.65% increase year-over-year[6] - Net profit attributable to shareholders decreased by 10.31% to ¥156,699,380.93 in Q3 2023[6] - The net profit excluding non-recurring gains and losses was ¥146,390,169.67, down 14.68% compared to the same period last year[6] - Total operating revenue for the current period reached ¥2,925,537,429.00, an increase of 4.48% from ¥2,800,058,651.27 in the previous period[29] - Net profit for the current period was ¥475,952,284.31, slightly up from ¥475,470,952.50 in the previous period, reflecting a growth of 0.10%[29] - The total comprehensive income attributable to the parent company's owners was CNY 473,291,140.84, compared to CNY 472,409,977.97 in the previous period, showing a slight increase[33] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date period decreased by 26.56% to ¥500,457,167.03[6] - Cash flow from operating activities generated a net amount of ¥500,457,167.03, down from ¥681,416,066.30 in the previous period[30] - Cash flow from investing activities resulted in a net outflow of ¥600,246,432.81, slightly improved from a net outflow of ¥617,421,539.09 in the previous period[30] - Cash and cash equivalents were reported at CNY 1,243,076,314.62, down from CNY 1,548,475,399.92, indicating a decrease of approximately 19.7%[22] - Cash and cash equivalents at the end of the period totaled ¥1,205,169,946.47, down from ¥1,401,844,562.75 at the end of the previous period[30] Assets and Liabilities - Total assets increased by 3.50% to ¥7,620,113,019.74 compared to the end of the previous year[6] - The company's current assets decreased to CNY 2,733,581,937.57 from CNY 3,281,165,784.46, representing a decline of about 16.7%[22] - The total liabilities increased to CNY 2,233,850,745.76 from CNY 2,190,585,660.02, marking an increase of about 2.0%[27] - The company's equity attributable to shareholders rose by 4.18% to ¥5,361,097,357.80[6] - The company's equity attributable to shareholders rose to CNY 5,361,097,357.80 from CNY 5,146,123,375.50, showing an increase of approximately 4.2%[27] - The total non-current assets increased to CNY 4,886,531,082.17 from CNY 4,081,390,078.48, representing a growth of approximately 19.8%[22] Expenses and Costs - Total operating costs increased to ¥2,433,056,491.69, up 5.77% from ¥2,300,367,857.99 in the previous period[29] - Research and development expenses rose to ¥259,456,442.07, an increase of 5.67% compared to ¥246,403,668.53 in the previous period[29] - The company reported a decrease in sales expenses to ¥605,886,403.51, down 10.77% from ¥679,200,078.77 in the previous period[29] - The company's financial expenses showed improvement, with a net income of -¥38,235,729.66 compared to -¥59,376,378.44 in the previous period[29] Other Financial Metrics - The weighted average return on equity decreased by 0.41 percentage points to 2.97% for Q3 2023[6] - The company's total liabilities to equity ratio stands at approximately 41.5%, indicating a stable leverage position[27] - The basic and diluted earnings per share remained stable at CNY 0.55[33] - The net profit attributable to minority shareholders was CNY 3,342,046.57, compared to CNY 3,737,377.35 in the previous period, indicating a decrease[33]